SGLT2 inhibitors

Victoria SochaDiabetes and Hypertension | October 5, 2023
In those with more nephrology visits in the proceeding 12 months, the odds of SGLT2 inhibitor prescription were lower.
Read More
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | April 18, 2023
Sodium-glucose transport protein 2 (SGLT2) inhibitors (SGLT2i), or gliflozins, block SGLT2 cotransporters in the ...
Victoria SochaDiabetes and Hypertension | January 23, 2023
During a poster session at the American Society of Nephrology Kidney Week 2022, Thomas Mavrakanas, MD, MSc, and ...
Victoria SochaDiabetes and Hypertension | December 8, 2022
Previous studies have shown that the use of sodium glucose linked transporter inhibitors (SGLT-2i) in nontransplant ...
DocWire News EditorsCardiology | May 13, 2022
Coronary Heart Disease Risk Factors and Serum Expression Analysis ...
Amit Goyal, MDCardioNerds | May 10, 2021
Editor's Note: This content was written by Amit Goyal, MD, a cardiology fellow at the Cleveland Clinic, and co-founder ...
Victoria SochaAcute Kidney Injury | May 6, 2021
Donna Shu-Han Lin, MD, and colleagues at National Taiwan University Hospital, Taipei, Taiwan, conducted a meta-analysis ...
Victoria SochaAcute Kidney Injury | April 23, 2021
Of the approximately one in 11 adults worldwide with diabetes, 90% have type 2 diabetes mellitus. Globally, the ...
DocWire News EditorsHeart Failure | September 16, 2020
The manufacturers of Jardiance (empagliflozin) accounted that the FDA has granted FastTrack status to the drug for the ...
DocWire News EditorsHeart Failure | July 23, 2020
Dapagliflozin appears safe and effective across different diuretic subgroups of heart failure patients, a new analysis ...
DocWire News EditorsCardiology | February 7, 2020
This week's edition features some drug updates: one on SGLT-2 inhibitors in type 2 diabetic patients, and another on ...
DocWire News EditorsHFSA 19 | September 18, 2019
The 2019 Heart Failure Society of America Scientific Meeting (HFSA 2019) in Philadelphia has wrapped up. DocWire News ...
DocWire News EditorsAmerican Diabetes Association Scientific Sessions 2019 | June 11, 2019
A majority of patients with type 2 diabetes mellitus, atherosclerotic cardiovascular disease, and low density ...
DocWire News EditorsCardiology | April 19, 2019
This week's edition includes some troubling findings for statins, good things happening with canagliflozin, a new add-on ...
DocWire News EditorsCardiology | April 18, 2019
Semaglutide (OZEMPIC) taken weekly as an add-on therapy to sodium-glucose cotransporter-2 (SGLT-2) inhibitors was ...
DocWire News EditorsCardiology | January 2, 2019
Canagliflozin, recently approved for the reduction of heart attack and stroke risk in type 2 diabetics with known ...
DocWire News EditorsAHA Scientific Sessions 2018 | November 20, 2018
Subodh Verma, MD, of St. Michael's Hospital and University of Toronto, talks with DocWire News about the EMPA-HEART ...
DocWire News EditorsAHA Scientific Sessions 2018 | November 19, 2018
Stephen D. Wiviott, MD, talks with DocWire News, about the results and implications from the Dapagliflozin Effect on ...
Kaitlyn D’OnofrioDiabetes | November 16, 2018
Some medications for diabetes may come with the increased odds of lower limb amputation, according to a recent study.  ...
Advertisement
Advertisement
Latest News

November 30, 2023